Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | CASP6 | P55212 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | TAS1R3 | Q7RTX0 | 4/20 | 0.50 |
| ▸ | TAS1R1 | Q7RTX1 | 4/20 | 0.50 |
| ▸ | SIRT1 | Q96EB6 | 4/20 | 0.50 |
| ▸ | DHODH | Q02127 | 1/20 | 0.50 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.49 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CDKN1A | P38936 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5456630 | 0.89 | BRD3 (0.54) | MAPTALOX15SMN1; SMN2GAACASP6 | |
| SCHEMBL5459706 | 0.82 | BRD3 (0.59) | MAPTALOX15SMN1; SMN2GAACASP6 | |
| SCHEMBL5454074 | 0.82 | BRD3 (0.67) | MAPTALOX15SMN1; SMN2GAACASP6 | |
| SCHEMBL4021476 | 0.81 | SIRT1 (0.61) | MAPTALOX15SMN1; SMN2GAACASP6 | |
| SCHEMBL5460625 | 0.81 | SIRT1 (0.53) | MAPTALOX15SMN1; SMN2GAACASP6 | |
| SCHEMBL5445807 | 0.80 | GAA (0.61) | MAPTALOX15SMN1; SMN2GAACASP6 | |
| SCHEMBL5452182 | 0.79 | GAA (0.55) | MAPTALOX15SMN1; SMN2GAACASP6 | |
| SCHEMBL5450144 | 0.79 | BRD3 (0.63) | MAPTALOX15SMN1; SMN2GAACASP6 | |
| SCHEMBL5459636 | 0.79 | GAA (0.55) | MAPTALOX15SMN1; SMN2GAACASP6 | |
| SCHEMBL5459031 | 0.79 | SMN1; SMN2 (0.63) | MAPTALOX15SMN1; SMN2GAACASP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070276009-A1 | Compositions and Methods for Viral Inhibition | CHIRON CORPORATION | 2007-11-29 | — | — | US | disclosed |
| US-20070276009-A1 | Compositions and Methods for Viral Inhibition | CHIRON CORPORATION | 2007-11-29 | — | — | US | disclosed |
| US-20070276009-A1 | Compositions and Methods for Viral Inhibition | CHIRON CORPORATION | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276009-A1 | Compositions and Methods for Viral Inhibition | MAVS, SARS1, ZC3HAV1 | MAPT 3817/4885ALOX15 655/4885SMN1; SMN2 4824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.